A Phase II Study to Explore the Effect of Different Dose of DMTA07 Combine With Amlodipine Treatment in Patients With Hypertension
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 111
- 试验地点
- 8
- 主要终点
- *SBP reduction=SBP each visit- SBPvisit2
研究概览
简要总结
The purpose of this study is to compare the different dose of DMTA07 (DM) combine with amlodipine in the treatment of mild to moderate essential hypertension, and to define the optimized dose of DM in the combination therapy.
详细描述
To compare the different dose of DM combine with amlodipine in the treatment of mild to moderate essential hypertension, and to define the optimized dose of DM in the combination therapy.
The purpose of this study is to compare the antihypertensive efficacy and tolerability of different dose of DM combines with amlodipine treatment, further to explore the optimized combination dose of DM.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 50 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patient aged between 50 to 75 years old (both included);
- •Patient with mild to moderate essential hypertension at enrollment, which defined as the following:
- •Patient must have mean sitting SBP ≥140 and <180 mmHg or mean sitting DBP ≥90 and <110 mmHg at enrollment;
- •Patient with normal serum potassium;
- •Patient or his/her legally acceptance representative has signed the written informed consent form.
排除标准
- •Patient with severe hypertension (mean sitting DBP ≥ 110 mmHg or mean sitting SBP ≥ 180 mmHg);
- •Patient with secondary hypertension, such as coarctation of aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's disease, pheochromocytoma, polycystic kidney disease, etc;
- •Patient is under treatment with beta-blocker prior to enrollment;
- •A definite diagnosis or unstable of cardiovascular disease, including angina pectoris, myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, transient ischemic attack, stroke, arrhythmia and heart failure within 3 months before signing the written informed consent form;
- •Patient with concomitant endocrine diseases or type 1 Diabetes Mellitus;
- •Patient with type 2 Diabetes Mellitus with poor glucose control (glycosylated hemoglobin > 9% or fasting blood sugar > 250 mg/dL at enrollment) or under insulin treatment;
- •Patient with clinically unstable disease such as known collagen or auto-immune disease or other malignant disease requiring current medication;
- •Patient with bilateral renal artery stenosis, solitary kidney or post renal transplant;
- •Patient with clinically relevant hematological disease;
- •Hepatic or renal dysfunction as defined by the following parameters:
- •ALT or AST > 2 times upper limit of normal,
- •Total bilirubin > 2 times upper limit of normal,
- •Serum creatinine >2.0 mg/dl;
- •Female patient who is pregnant or lactating;
- •Patient with substance abuse (including alcohol) history for the past two years;
- •Known or suspected contraindications, including allergy to DMTA07 or calcium channel blockers;
- •Patient received other investigational drug or device within 30 days before signing the written informed consent form;
- •Patient with any other serious disease considered by the investigator(s) not in the condition to enter the trial.
研究组 & 干预措施
AM 5 + DM 0
Amlodipine 5 mg + DMTA07 0mg, once daily
干预措施: AM 5 + DM 0 (Drug)
AM 5 + DM 2.5
Amlodipine 5 mg + DMTA07 2.5mg, once daily
干预措施: AM 5 + DM 0 (Drug)
AM 5 + DM 2.5
Amlodipine 5 mg + DMTA07 2.5mg, once daily
干预措施: AM 5 + DM 2.5 (Drug)
AM 5 + DM 7.5
Amlodipine 5 mg + DMTA07 7.5mg, once daily
干预措施: AM 5 + DM 0 (Drug)
AM 5 + DM 7.5
Amlodipine 5 mg + DMTA07 7.5mg, once daily
干预措施: AM 5 + DM 2.5 (Drug)
AM 5 + DM 7.5
Amlodipine 5 mg + DMTA07 7.5mg, once daily
干预措施: AM 5 + DM 7.5 (Drug)
AM 5 + DM 30
Amlodipine 5 mg + DMTA07 30mg, once daily
干预措施: AM 5 + DM 0 (Drug)
AM 5 + DM 30
Amlodipine 5 mg + DMTA07 30mg, once daily
干预措施: AM 5 + DM 2.5 (Drug)
AM 5 + DM 30
Amlodipine 5 mg + DMTA07 30mg, once daily
干预措施: AM 5 + DM 7.5 (Drug)
AM 5 + DM 30
Amlodipine 5 mg + DMTA07 30mg, once daily
干预措施: AM 5 + DM 30 (Drug)
结局指标
主要结局
*SBP reduction=SBP each visit- SBPvisit2
时间窗: 14 weeks
The primary objective of this study is to compare the sitting systolic blood pressure (mmHg) reduction\* between four dose regimens, the baseline is defined as the actual SBP value after 2 weeks of amlodipine run-in period
次要结局
- The secondary objectives of the study include: Efficacy/Safety(14 weeks)